Austrian Breast & Colorectal Cancer Study Group

Recent papers from Austrian Breast & Colorectal Cancer Study Group

1. Treatment-related neutropenia as predictor of response to adjuvant palbociclib in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)JNCI Journal of the National Cancer Institute · 2026
2. Expanding the ESMO-MCBS: integrating organ preservation into clinical benefit assessment in rectal cancerESMO Gastrointestinal Oncology · 2026
3. Validation of the advanced‐stage Hodgkin lymphoma international prognostic index (A‐HIPI) in the GHSG HD21 trialHemaSphere · 2026
4. Impact of Response to Hypomethylating Agent‐Based Therapy on Survival Outcomes in the Context of Baseline Clinical‐Molecular Risk and Transplant Status in Patients With Higher‐Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS)American Journal of Hematology · 2026
5. Central Nervous System Metastases in Metastatic Breast Cancer: Incidence, Subtype-Specific Patterns, and Outcomes from the Austrian AGMT_MBC RegistryThe Breast · 2026
6. Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trialAnnals of Oncology · 2026
7. Common analysis pitfalls in longitudinal ctDNA studies: lead time, sensitivity and immortal time biasEBioMedicine · 2026
8. The Xpert Breast Cancer Insight Test Predicts Distant Recurrence and Overall Survival in ER-Positive, HER2-Negative Early Breast CancerClinical Breast Cancer · 2026
9. Glofitamab in Heavily Pretreated Mantle Cell Lymphoma Patients: A Multicenter Real‐World Case SerieseJHaem · 2026
10. Reducing breast cancer recurrences with CDK4/6 inhibitor treatment of HR-positive, HER2-negative early stage breast cancer from a societal perspectiveHealth Economics Review · 2026
11. Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancerThe Oncologist · 2026
12. Disease-free survival (DFS) and time to recurrence (TTR) with circulating tumor (ct) DNA–based decision for adjuvant treatment in colon cancer stage II (CIRCULATE): An AIO (KRK-0217)/ABCSG trial.Journal of Clinical Oncology · 2026
13. Chemotherapy for patients with circulating tumour DNA positive, stage II colon cancer (CIRCULATE) – an AIO / ABCSG trialAnnals of Oncology · 2026
14. BRCA-P: Can denosumab reduce breast cancer risk in BRCA1 mutation carriers?Journal of Clinical Oncology · 2026
15. The impact of reduction in intraoperative frozen sections on positive margin findings in the final pathology report.Journal of Clinical Oncology · 2026
16. Outcome of patients with lung cancer treated with stereotactic body radiotherapy for bone oligometastases - a European multicenter cohort studyRadiation Oncology · 2026
17. Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trialESMO Open · 2026
18. Omitting axillary dissection in breast cancer patients with one to two positive sentinel nodes undergoing mastectomy: a retrospective and prospective cohort study with a target trial emulationInternational Journal of Surgery · 2026
19. Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trialnpj Breast Cancer · 2026
20. Characterization, immune cell phenotyping and differential gene expression analysis of brain metastases and primary breast cancer samplesScientific Reports · 2026